Last reviewed · How we verify
Multi OIT
At a glance
| Generic name | Multi OIT |
|---|---|
| Sponsor | Xiu-Min Li |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Low Dose Multi-Nut Oral Immunotherapy in Pre-schoolers With a Multi-Nut Allergy (NA)
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (PHASE3)
- Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) (PHASE2)
- Low Dose Multi-OIT for Food Allergy (LoMo) (PHASE2)
- Omalizumab to Accelerate a Symptom-driven Multi-food OIT (PHASE2)
- ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (PHASE1, PHASE2)
- Open-label Extension Study of ADP101 (PHASE1, PHASE2)
- E-B-FAHF-2, Multi OIT and Xolair for Food Allergy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multi OIT CI brief — competitive landscape report
- Multi OIT updates RSS · CI watch RSS
- Xiu-Min Li portfolio CI